The new MDR: opportunity instead of hindranceMay 2021The new Medical Device Regulation (MDR) came into force this month. The implementation is a challenge. However, for manufacturers who rely on highly qualified, external experts in the process, it can also be a great opportunity to quickly place products into the EU market.
Payrolling: The route to exciting projects in SwitzerlandMarch 2021Are you a highly qualified life sciences expert looking for a challenging global project? Let us briefly and concisely inform you about the Swiss labour market’s special features and what you should know about payrolling, a well-established type of contract in Switzerland. 
Placement of freelancers within the framework of MSP programmesJanuary 2021In order to appropriately fill open positions and projects in the pharma & biotech and medical technology industry at short notice, K-Recruiting places freelance specialists with life sciences companies. In addition, K-Recruiting also fills open positions within the framework of MSP programmes, i.e. in cooperation with an MSP provider, and so has its own internal MSP team. But what is actually behind the term "MSP" and this model?
The main forms of personnel recruitment – what you need to knowMay 2020When it comes to filling vacancies quickly and effectively, companies no longer rely on their own recruiting departments. Their staffing requirements are increasingly being met by external recruitment consultants. In the following overview we will show you what models exist here in practice, and what advantages and disadvantages they offer.
New impetus for the life sciences in 2020 – future prospectsFebruary 2020The life science sector has been experiencing a phase of stable growth for years now. This review deals with topics relating to the coming year and the challenge of creating new value, seizing opportunities and investing in the future in a targeted manner. 2020 will be a year of new superlatives: both for the sector itself and for business professionals in the life science markets.
Novartis Phase II substance as promising anti-tumor combination therapyMarch 2018The absolute number of new cases of cancer has almost doubled since the early 1970s in Germany. However, the mortality caused by cancer in Germany, as in most other wealthy countries, has declined significantly. This is mainly due to progress in therapy and probably also in early detection [1]. Every year, the global pharmaceutical industry […]
The new EU Counterfeiting Directive 2011/62 / EU — a major challenge for pharmaceutical companiesDecember 2017The new EU Counterfeiting Directive 2011/62 / EU — a major challenge for pharmaceutical companies The EU Counterfeiting Directive 2011/62 / EU was adopted in 2016 to minimize the risk of counterfeit prescription drugs in the legal supply chain. The change in the existing directive was prompted by the rapid increase in the number of […]
What are the challenges for companies through the new medical device regulation?July 2017On May 25th this year, the new medical device regulation came into force ("MDR" for "Medical Device Regulation"). This has significantly increased the workload for affected companies, as the new directives set high and changed requirements. There will inevitably be work peaks due to that.
Increasing need for external freelance support in the Life Sciences industryJune 2017Over time, companies in the Life Sciences industry, especially pharmaceutical and Medical Device companies, are confronted with new challenges more than ever. Here a new guideline, there a change in the corporate strategy or possibly the merger with a partner company and then, there is always the digitalization.
